Spero Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Spero Therapeutics, Inc. (SPRO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 1.00% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2023-03-30
- Spero Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was 1.00%, a 66.67% increase from fiscal 2021.
- Spero Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was 0.60%, a 33.33% decline from fiscal 2020.
- Spero Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2020 was 0.90%, a 18.18% decline from fiscal 2019.
- Spero Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2019 was 1.10%, a 8.33% decline from fiscal 2018.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2022-12-31 | 1.00% 10-K · filed 2023-03-30 |
| 2021-12-31 | 0.60% 10-K · filed 2023-03-30 |
| 2020-12-31 | 0.90% 10-K · filed 2022-03-31 |
| 2019-12-31 | 1.10% 10-K · filed 2021-03-11 |
| 2018-12-31 | 1.20% 10-K · filed 2020-03-16 |
| 2017-12-31 | -0.10% 10-K · filed 2019-03-14 |
| 2016-12-31 | 4.80% 10-K · filed 2019-03-14 |
| 2015-12-31 | 10.20% 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |